Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Micromet Signs Deals With Bayer And Lonza
by Ann M. Thayer
December 7, 2009
| A version of this story appeared in
Volume 87, Issue 49
German biotech firm Micromet will work with Bayer Schering Pharma to develop a new antibody against an undisclosed solid tumor target. Micromet’s BiTE antibodies help direct the body’s cell-killing T cells against tumor cells. The two companies will collaborate through Phase I clinical trials, after which Bayer will assume control. Bayer will pay Micromet $7.5 million up front and up to $430 million in milestone payments. Separately, Micromet has hired Lonza to conduct process development and manufacturing of blinatumomab, an antibody in clinical studies for treating hematologic cancers.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter